Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA7 | P43166 | 3/20 | 0.67 |
| ▸ | CA9 | Q16790 | 3/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258832 | 1.00 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| Benzoic Acid SCHEMBL5695899 | 0.87 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11692721 | 0.86 | CA1 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL109588 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2708451 | 0.84 | SLC6A4 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30301996 | 0.84 | SLC6A4 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL410760 | 0.83 | CA1 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL112046 | 0.82 | CES2 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1977659 | 0.81 | SLC6A4 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29406430 | 0.81 | SLC6A4 (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112718002-A | Preparation method of nicarparii intermediate | 杭州君领医药科技有限公司 | 2021-04-30 | — | — | CN | claimed |
| CN-110078625-B | Method for preparing intermediate for ovarian cancer medicine | 张磊 | 2020-04-14 | — | — | CN | claimed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-20250333421-A1 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-30 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4581032-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250171460-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| CN-115611810-B | Substituted pyrazoles, composition containing same and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2025024543-A1 | TRICYCLIC UBE2K MODULATORS AND METHODS FOR THEIR USE | BPGBIO, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-12172989-B2 | Histone acetyltransferase (HAT) inhibitor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-12-24 | — | — | US | disclosed |
| WO-2005000305-A1 | 3-AMINOPIPERIDINES AND 3-AMINOQUINUCLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| CN-1128025-A | Benzoxazinones and benzothiazinones having therapeutic activity | ITALFARMACO SPA (IT) | 1996-07-31 | — | — | CN | disclosed |
| EP-0711286-A1 | BENZOXAZINONES AND BENZOTHIAZINONES ENDOWED WITH THERAPEUTIC ACTIVITY | ITALFARMACO S.p.A. (IT) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004048-A1 | BENZOXAZINONES AND BENZOTHIAZINONES ENDOWED WITH THERAPEUTIC ACTIVITY | ITALFARMACO S.P.A. (IT) | 1995-02-09 | — | — | WO | disclosed |
| US-5068248-A | Analgesics, antipyretics and antiinflammatory agents | MERCK & CO., INC. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0160408-B1 | BENZOTHIOPHENES, THEIR PRODUCTION AND USE, AND COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4760086-A | N-alkenyl-3-hydroxybenzo[b]thiophene-2-carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0160408-A1 | Benzothiophenes, their production and use, and compositions containing them | MERCK & CO. INC. (US) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171460-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | SREBF2, LIPG, KLF5 | CA12 4810/4885CA1 4872/4885CA2 4309/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | CA12 1832/4885CA1 2402/4885CA2 1446/4885 |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | CBR1, CNR1, CBR3 | CA12 483/4885CA1 1010/4885CA2 429/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | CA12 4808/4885CA1 4853/4885CA2 4637/4885 |
| US-12172989-B2 | Histone acetyltransferase (HAT) inhibitor and use thereof | EP300, HDAC11, HDAC1 | CA12 4376/4885CA1 3554/4885CA2 4278/4885 |
| US-20250333421-A1 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | MEN1, MLLT1, MPL | CA12 4758/4885CA1 4757/4885CA2 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.